R3327H Xenograft Rat Model Service for Prostate Cancer

The R3327H xenograft rat model recapitulates the androgen-dependent, well-differentiated biology of prostate adenocarcinoma within a host system that supports longitudinal hormone manipulation and serial pharmacodynamic sampling. Alfa Cytology designs and executes R3327H-based rat xenograft studies with specialized expertise in endocrine modulation protocols, delivering reproducible tumor response data and comprehensive histopathological endpoints that inform your prostate cancer therapeutic development from mechanistic proof-of-concept through late-stage efficacy validation.

Overview of R3327H Xenograft Rat Model for Prostate Cancer

The Dunning R3327H tumor is a rat prostatic adenocarcinoma that arose spontaneously in 1961 from the dorsal lobe of a Copenhagen rat. It stands as one of the most extensively characterized and historically significant experimental models of hormone-dependent prostate cancer. The H-subline is defined by well-differentiated glandular architecture, robust expression of androgen receptor (AR), and secretion of prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP)—molecular hallmarks that closely parallel the androgen-responsive subset of human prostate adenocarcinoma. When established as a xenograft in immunodeficient rats, R3327H tumors exhibit relatively slow but highly reproducible growth kinetics, with tumor volumes typically doubling over intervals of several weeks rather than days. This deliberate proliferative tempo makes the model especially well-suited for evaluating chronic endocrine interventions, including androgen deprivation therapy, anti-androgen blockade, and combined modality regimens that require extended observation windows to manifest therapeutic benefit.

Fig 1. Timeline highlighting important milestones in the use of animal models for prostate cancer research. (Nascimento-Gonçalves, Elisabete, et al., 2025)

Beyond its utility in monotherapy assessment, the R3327H rat xenograft platform has served as the foundational model for validating LHRH agonists and antagonists, complete versus partial androgen withdrawal strategies, and the integration of cytostatic agents with hormonal backbone therapy. The model's faithful retention of AR signaling, steroid metabolism pathways, and differentiated secretory phenotype enables researchers to interrogate ligand-driven transcriptional programs, receptor occupancy dynamics, and downstream effector modulation with a degree of physiological fidelity that human cell line xenografts often fail to replicate. Orthotopic implantation into the rat prostate capsule or dorsal lobe preserves the native stromal-epithelial interactions and vascular supply characteristic of the glandular microenvironment, while subcutaneous engraftment offers straightforward accessibility for repeated tumor biopsies and direct intratumoral dosing. Collectively, these attributes position the R3327H rat model as an indispensable bridge between in vitro AR pharmacology and the clinical evaluation of hormone-directed prostate cancer therapeutics.

Cell Line Information: R3327H

The R3327H tumor system encompasses both the original tissue-derived explant and several derivative epithelial and stromal cell lines that retain the parental tumor's steroid responsiveness and differentiated secretory phenotype. The table below consolidates the essential biological and molecular characteristics pertinent to xenograft model construction and endocrine therapeutic screening.

Our Services

Alfa Cytology offers specialized R3327H xenograft rat model services designed to meet the unique demands of prostate cancer endocrine therapeutic development. Our capabilities span hormone-responsive tumor establishment, surgical orthotopic implantation into the prostate capsule, castration-based androgen deprivation protocols, and comprehensive endpoint analysis encompassing AR pathway modulation, PSA kinetics, and histological differentiation scoring. Whether your program targets AR degradation, partial agonism, or complete androgen blockade, we provide the methodological rigor and scientific insight to generate preclinical data that withstands regulatory and peer-review scrutiny.

Workflow of R3327H Xenograft Rat Model Construction

Establishing a reproducible R3327H xenograft rat model demands careful attention to hormone milieu, surgical precision, and longitudinal endocrine monitoring. The workflow below delineates each phase from tumor preparation through terminal analysis, ensuring consistent engraftment and biologically meaningful response data.

1. Tumor Tissue or Cell Line Preparation and QC: R3327H tumor tissue is harvested from stock animals or derivative cell lines (e.g., R3327H-G8-A1, HUNC-E) are expanded in vitro under steroid-depleted or supplemented conditions as dictated by the study design. Cells undergo STR authentication, mycoplasma PCR screening, and passage-number logging. For tissue fragment models, tumor pieces (2–3 mm³) are prepared under sterile conditions and maintained on ice until implantation. Viability and sterility are confirmed prior to inoculation.
2. Recipient Rat Acclimatization and Hormonal Baseline Assessment: Immunodeficient rats—typically athymic nude (RNU) or severely immunocompromised strains—are acclimatized for a minimum of five days under SPF conditions. Baseline body weights, serum testosterone levels, and clinical observations are documented. Animals are randomized into cohorts stratified by body mass and baseline androgen status.
3. Tumor Cell or Tissue Implantation: For subcutaneous models, 100–200 µL of single-cell suspension (1–5 × 10⁶ viable cells) or tumor fragments are implanted into the subcutaneous flank. For orthotopic models, a midline laparotomy exposes the prostate capsule, and cell suspension or tissue fragments are deposited into the dorsal lobe under direct visualization. The abdominal wall is closed in layers, and post-operative analgesia is administered.
4. Post-Operative Monitoring and Tumor Surveillance: Animals are housed in individually ventilated cages with daily health checks. Tumor dimensions are measured two to three times weekly using digital calipers, with volumes calculated as: Volume = (length × width²) × 0.5. Body weights and clinical scores are documented concurrently. Serum PSA and testosterone are monitored weekly to assess hormonal status and tumor secretory activity.
5. Endocrine Manipulation and Therapeutic Intervention: Upon tumors reaching the target volume (typically 100–200 mm³), animals are randomized into treatment arms. Endocrine manipulations—including surgical castration, chemical castration (LHRH agonists/antagonists), anti-androgen administration (e.g., bicalutamide, enzalutamide), or combined androgen blockade—are initiated according to the protocol. Test compounds are delivered via oral gavage, subcutaneous injection, or continuous infusion.
6. Serial Biomarker and Pharmacokinetic Sampling: Blood is collected via tail vein or saphenous vein puncture (up to 300 µL per draw) at predetermined intervals for serum testosterone, PSA, PAP, and drug concentration quantification. Interim tumor biopsies may be procured for AR occupancy, downstream signaling, and differentiation marker analysis.
7. Terminal Necropsy and Comprehensive Endpoint Analysis: At study termination, animals are humanely euthanized per IACUC protocols. Primary tumors are excised, weighed, photographed, and allocated for histopathology, immunohistochemistry (AR, PSA, PAP, Ki-67, cleaved caspase-3), Western blotting, and RNA sequencing. Distant organs—lymph nodes, lung, liver, bone—are examined for metastatic deposits. Seminal vesicles and testes are weighed to confirm castration efficacy or androgen supplementation status.

Fig 2. R3327H Xenograft Rat Model construction workflow.

Case Study-R3327H Xenograft Rat Model Development

In a recent preclinical evaluation, male athymic nude rats received subcutaneous implantation of R3327H tumor fragments, achieving a 100% engraftment rate with palpable tumors detectable within 14–21 days. Tumors exhibited well-differentiated glandular architecture with prominent luminal structures, diffuse AR nuclear staining, and robust PSA immunoreactivity—confirming faithful recapitulation of the parental tumor's hormone-responsive phenotype. A parallel cohort underwent surgical castration on day 14 post-implantation, resulting in marked tumor growth arrest and measurable reduction in serum PSA levels relative to intact controls. A treatment arm receiving a novel AR-targeted agent in combination with androgen deprivation demonstrated further suppression of tumor volume, accompanied by down-regulation of AR-driven gene expression and increased apoptotic index within residual tumor tissue. These outcomes illustrate the translational utility of the R3327H rat xenograft platform for benchmarking hormonal therapeutic strategies and dissecting AR-dependent response mechanisms in prostate cancer.

Why Choose Alfa Cytology?

Prostate cancer drug development demands a preclinical partner with deep expertise in endocrine biology, surgical orthotopic technique, and steroid pathway analytics. Alfa Cytology brings decades of collective experience in hormone-dependent tumor modeling to every R3327H rat xenograft engagement, ensuring your study generates data that resonates with clinical relevance and regulatory expectations.

• Hormone-Specialized Model Qualification — Each R3327H batch is validated for AR expression, PSA/PAP secretion, and androgen-responsive growth kinetics prior to client study initiation, ensuring biological fidelity from the first engraftment.
• Precision Endocrine Protocols — Our team designs and executes castration, testosterone supplementation, LHRH manipulation, and anti-androgen blockade regimens with exacting hormonal monitoring to mirror clinical treatment paradigms.
• Orthotopic Surgical Excellence — We perform prostate capsule and dorsal lobe implantations with high reproducibility, preserving native stromal-epithelial architecture and enabling studies of local invasion and glandular microenvironment dynamics.
• Integrated Steroid Pathway Analytics — In-house capabilities for serum testosterone, PSA, PAP quantification, AR occupancy assays, and downstream signaling analysis (e.g., PSA gene expression, FKBP5 modulation) deliver mechanistic depth beyond tumor volume metrics.
• Flexible Combination Study Architectures — We accommodate multi-arm designs spanning monotherapy, sequential hormonal therapy, androgen withdrawal plus cytostatic combination, and cross-resistance profiling aligned with your compound's mechanism of action.
• Regulatory-Grade Compliance — All protocols are IACUC-approved, with real-time data capture, chain-of-custody documentation, and audited final reports structured for IND submissions and investor-facing presentations.

Contact Us

Seeking a validated, hormone-responsive prostate cancer model to advance your AR-targeted therapeutic program? Contact us today to discuss your study objectives, compound profile, and endocrine manipulation requirements. Our preclinical oncology team will partner with you to architect a tailored R3327H xenograft rat model strategy that delivers robust, publication-ready data and accelerates your candidate toward IND-enabling milestones. Whether you require a castration-responsive subcutaneous screen or a sophisticated orthotopic model with longitudinal PSA monitoring and AR pathway profiling, Alfa Cytology is ready to execute with precision and scientific rigor.

For research use only. Not intended for any clinical use.